Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
02/2003
02/13/2003WO2002094275A8 Use of estrogen compounds to increase libido in women
02/13/2003WO2002089730A3 Compounds and methods for the modulation of cd154
02/13/2003WO2002087574A3 Use of pyridoindolone derivatives for preparing anticancer medicines
02/13/2003WO2002083079A3 Aerosol compositions containing formoterol for delivery to the lungs via nebulization
02/13/2003WO2002080849A3 Chemotherapeutic induction of egr-1 promoter activity
02/13/2003WO2002078638A3 Morpholino imaging and therapy
02/13/2003WO2002069925A3 Use of $g(a)-lipoic acid in cosmetic or dermatological preparations
02/13/2003WO2002062810A3 Linkable sialyl lewis x analogs
02/13/2003WO2002060482A3 Perylenequinones for use with immunotherapy agents
02/13/2003WO2002060454B1 Use of dinucleoside polyphosphate to stimulate removal of fluid in retinal disorders
02/13/2003WO2002060427A3 Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
02/13/2003WO2002051434A3 Modulation of smr1-nep interactions in cns disorders giving rise to mental disorders
02/13/2003WO2002043765A9 Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
02/13/2003WO2002038141A9 Compositions and methods for treatment of mild cognitive impairment
02/13/2003WO2002038129A3 Delayed-release pharmaceutical formulations containing proinsulin c-peptide
02/13/2003WO2002032958A3 Polynucleotide and polypeptide sequences of human dendritic cell immunoreceptors
02/13/2003WO2002015942A8 Method for the identification of agents that inhibit or promote cataracts and uses thereof
02/13/2003WO2002013791A3 Steroid hormones as transfer agents
02/13/2003WO2002009755A3 Apo-2l receptor agonist and cpt-11 synergism
02/13/2003WO2002007753A3 Method for treating unstable angina pectoris
02/13/2003WO2002006515A3 Method of diagnosing, monitoring, staging, imaging and treating colon cancer
02/13/2003WO2001094951A9 Inhibitors of c-reactive protein induced inflammation
02/13/2003WO2001092567A3 Novel target genes for diseases of the heart
02/13/2003WO2001087286A3 Antisense enzyme inhibitors for improving pharmacokinetics of a drug
02/13/2003US20030033623 Animal model for use in the treatment and diagnosis of nervous system disorders
02/13/2003US20030032995 Thermotherapy via targeted delivery of nanoscale magnetic particles
02/13/2003US20030032917 Use of a blood-flow decrease preventing agent in conjunction with insufflating gas
02/13/2003US20030032804 Methods of treating periodontal disease
02/13/2003US20030032791 Nucleotide sequences coding polypeptide for use in the treatment of metabolic, reproductive and eating disorders
02/13/2003US20030032674 Use of unsaturated fatty acids to treat severe inflammatory diseases
02/13/2003US20030032660 Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof
02/13/2003US20030032651 Intrathecal analgesia method
02/13/2003US20030032636 For the treatment of depression and other affective disorders.
02/13/2003US20030032634 Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
02/13/2003US20030032618 Pharmaceutical combinations
02/13/2003US20030032617 Administering nicotinamide, a nicotinamide agonist, a nicotinamide derivative, a nicotinamide metabolite or prodrugs thereof.
02/13/2003US20030032612 Inhibit expression of a gene in the operon; reducing bacterial resistance to antibiotics
02/13/2003US20030032605 EDTA and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections
02/13/2003US20030032596 Administering a compound that modulates the synthesis or expression of a target cellular gene, especially a Src kinase.
02/13/2003US20030032581 Pharmaceuticals for treating obesity
02/13/2003US20030032579 Therapeutic use of selective PDE10 inhibitors
02/13/2003US20030032097 DNA encoding human vanilloid receptor VR3
02/13/2003US20030032078 Screening therapies for vision defects; obtain sample containing oxidoreductase, incubate with modulator, monitor sample for reduction in enzyme activity
02/13/2003US20030032030 Determination of age in animals; obtain tissue sample from animal, monitor expression pattern of marker gene, compare to expression pattern in younger control, evaluate sample for aging
02/13/2003US20030031772 Mixtures of fructose and lactose as a low-calorie bulk sweetener with reduced glyemic index
02/13/2003US20030031730 Nasal passage cleaning composition
02/13/2003US20030031713 Extended release oral dosage composition
02/13/2003US20030031712 Opioid agonist /antagonist combinations
02/13/2003US20030031711 Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
02/13/2003US20030031702 Teratogenic drug such as isotretinoin and a contraceptive packaged together with a label specifying avoidance of pregnancy while taking the teratogenic drug; unit dosage
02/13/2003US20030031686 Exposing a source animal to an antigenic agent to elicit a T-cell mediated immune response, collecting an egg from the source that transfers cellular immunity to another animal in vivo
02/13/2003US20030031679 Immunomodulatory peptides derived from heat shock proteins and uses thereof
02/13/2003US20030031670 Diagnosis and treatment of malignant neoplasms
02/13/2003US20030031668 Treatment of immune complex disease with anti-CD40L antibodies
02/13/2003US20030031665 Anti-CD26 monoclonal antibodies as therapy for diseases associated with cells expressing CD26
02/13/2003US20030031664 For therapy of pulmonary embolism, myocardial infarction, thrombosis or stroke
02/13/2003US20030031659 For the treatment or prevention of a gastrointestinal infection caused by a pathogenic bacteria; for reducing insect and parasite populations in animal manure
02/13/2003US20030031657 Stem cells and their use in transplantation
02/13/2003CA2753329A1 Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
02/13/2003CA2457100A1 Taste masking composition
02/13/2003CA2456192A1 Pyrazole-derived kinase inhibitors and uses thereof
02/13/2003CA2456187A1 Pyrazole-derived kinase inhibitors and uses thereof
02/13/2003CA2456177A1 Erythropoietin and anti-tumor necrosis factor alpha combination therapy
02/13/2003CA2455843A1 Therapeutic delivery compositions and methods of use thereof
02/13/2003CA2455728A1 As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
02/13/2003CA2455711A1 As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
02/13/2003CA2455547A1 Use of vitamin e succinate and antiandrogen combination
02/13/2003CA2455520A1 Use of a pde4 inhibitor in combination with an anticholinergic agent for the treatment of pulmonary disease such as asthma
02/13/2003CA2455398A1 Use of peptide fragments of the calcium channel .alpha.-1 subunit, optionally comprising mutations, for screening molecules of therapeutic interest
02/13/2003CA2455358A1 Invert emulsion containing dhea
02/13/2003CA2455347A1 Neutral glycosphingolipids and glycosyl-sphingosines and methods for isolating the same
02/13/2003CA2455194A1 Vascular endothelial growth factor isoform having anti-angiogenic activity
02/13/2003CA2455154A1 Receptor, the use thereof, and mouse antibodies
02/13/2003CA2454937A1 Modulators of notch signalling for use in immunotherapy
02/13/2003CA2454935A1 Method for the nitration of phenolic compounds
02/13/2003CA2454159A1 Methods for assessing the risk of obesity based on allelic variations in the 5'-flanking region of the insulin gene
02/13/2003CA2454147A1 Inhibitor of dna methylation
02/13/2003CA2454066A1 Pulmonary formulation
02/13/2003CA2453939A1 Identification of specific tumor antigens by means of the selection of cdna libraries with sera
02/13/2003CA2453410A1 Methods for treating prostatitis
02/13/2003CA2452529A1 Use of a blood-flow decrease preventing agent in conjunction with insufflating gas
02/13/2003CA2452524A1 Use of lhrh-antagonists for the improvement of t-cell mediated immunity
02/13/2003CA2451942A1 Crystallized structure of type iv collagen nc1 domain hexamer
02/13/2003CA2450770A1 Combination of selective cox-2 inhibitor and lung surfactant for respiratory syndrome
02/13/2003CA2448235A1 Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
02/12/2003EP1283268A2 Recombinant vascular endothelial cell growth factor D (VEGF-D)
02/12/2003EP1283264A2 Interleukin-3 (IL-3) mutant polypeptides
02/12/2003EP1283260A1 Novel insulin/igf/relaxin family polypeptides and dnas thereof
02/12/2003EP1283057A1 Cell proliferation inhibitors
02/12/2003EP1283054A1 Drugs for complications of diabetes and neuropathy and utilization thereof
02/12/2003EP1283053A1 Inhibitors of HER3 activity
02/12/2003EP1283050A2 Improved therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products
02/12/2003EP1283043A1 Ophthalmic solution
02/12/2003EP1283041A1 Pharmaceutical compositions containing HIV-protease inhibitors
02/12/2003EP1282816A2 Improved assay techniques using nematode worms
02/12/2003EP1282706A2 Natrium-calcium exchanger protein
02/12/2003EP1282705A2 Endothelial differentiation gene 6-like g protein coupled receptor
02/12/2003EP1282700A1 Neuronal serine-threonine protein kinase
02/12/2003EP1282691A1 Method for preventing allograft rejection
02/12/2003EP1282689A1 Specific inhibitors of ribosome recycling factor (rrf)
1 ... 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 ... 1151